Adaptimmune Launches Tecelra Amid Strong Q2 Results
Adaptimmune's Tecelra launch marks progress in cell therapy, with strong Q2 financials and strategic plans for cancer treatment.
- Latest
- Trending
Adaptimmune's Tecelra launch marks progress in cell therapy, with strong Q2 financials and strategic plans for cancer treatment.
Published results show a 36-month survival rate of 20% with immunotherapy. ICI resistant group had a 72% 12-month OS rate. ...
ActivMAb's new "Antigen Virus" application complements drug discovery strategies for complex protein targets, according to Vaccinex CEO. Ongoing partnerships can ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.